Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings

Brian Ball, Amer Zeidan, Steven D. Gore, Thomas Prebet

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a significant advancement, HMA lead to responses in less than half of patients and for those that respond most will relapse. As such, there is a crucial need to improve frontline therapy approaches. One promising strategy involves combining azacitidine or decitabine with investigational or existing therapies with the goal of achieving synergistic activity and better patient outcomes. The purpose of this paper is to critically review the efficacy and safety of reported HMA-based combination regimens in patients with higher-risk MDS.

Original languageEnglish (US)
Pages (from-to)1022-1036
Number of pages15
JournalLeukemia and Lymphoma
Issue number5
StatePublished - May 4 2017


  • AML
  • DNA methyltransferase inhibitor
  • MDS
  • combination therapy
  • epigenetic
  • hypomethylating agent

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings'. Together they form a unique fingerprint.

Cite this